You.com Announces Partnership with Boardwave To Bring AI-Powered Productivity To The European Software Industry

18.9.2024 10:00:00 CEST | Business Wire | Press release

You.com, an AI-powered productivity engine, and Boardwave, a prominent community for 1,700+ European software leaders, have today announced a joint partnership to accelerate productivity and the adoption of AI in the European software industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918041701/en/

The new collaboration launches today at Boardwave Live in London and offers each of Boardwave’s members, and their leadership teams, access to You.com’s Team plan. This initiative equips European software entrepreneurs, founders, and CEOs with an all-in-one conversational AI platform for enhancing human productivity.

You.com offers access to the latest and most powerful Large Language Models (LLMs), enhanced with live web access. The platform features a range of powerful proprietary AI agents for research and problem-solving and the ability to create and share custom agents on top of any AI model for any task.

“Partnering with Boardwave is a great opportunity to get our AI into the hands of Europe’s software leaders. We’ve built You.com to tackle real productivity challenges. It’s not only about having the latest AI models; it’s about making them genuinely useful and trustworthy. Our APIs have been particularly popular in the SaaS community, allowing companies to integrate our AI capabilities directly into their workflows. We’re looking forward to partnering with Boardwave members to put these tools to work in their companies,” said Bryan McCann, CTO and co-founder of You.com, at the Boardwave Live event.

Boardwave Live is Boardwave’s Annual Conference, which draws together 450 of the best and brightest software Founders, CEOs, NEDs and Chairs from across Europe. During 2024, Boardwave has actively focussed on the use of “Practical AI” and how it can better support its community, using partnerships, events, mentorships and masterclasses. The partnership with You.com takes this to a deeper level and provides each of Boardwave’s members, and their executive teams, with access to all the popular LLMs.

“At Boardwave, we’re committed to accelerating the growth of European software companies. By partnering with You.com, we’re providing our members with access to an amazing toolkit of state-of-the-art AI, and all the major LLMS, that can significantly enhance their productivity. You.com’s offering includes access to all the latest AI models, best-in-class citations, reduced hallucinations, and improved accuracy, resulting in a more trustworthy experience. It’s a platform built by AI pioneers, and we’re excited to see how it will empower our community,” said Phill Robinson, CEO and co-founder of Boardwave.

For more information, visit www.you.com or www.boardwave.com.

For You.com’s APIs, visit https://you.com/business/api.

About You.com:

You.com is collaborative AI — for you, your team, and your business. You.com AI Agents maximize the productivity of knowledge workers through fast and accurate research and analysis, complex problem solving, content creation, and more. The company’s suite of APIs and end-to-end solutions drive revenue for businesses by becoming the foundation AI agent layer for their products and services. Founded by leading AI research scientists Richard Socher and Bryan McCann, You.com has raised $99 million from investors including Marc Benioff’s Time Ventures, Salesforce Ventures, NVIDIA, Gen Digital, SBVA, Georgian, Radical Ventures, Day One Ventures, Breyer Capital, Norwest Venture Partners, DuckDuckGo, Untapped Ventures, and others.

About Boardwave:

Boardwave is an impact-driven community of 1,700 European software founders and CEOs designed to help members accelerate their business growth, and to improve the overall position of Europe as a home for global software companies. Boardwave offers a programme of events, peer-to-peer mentoring and inspiration, as well as an online platform that connects European software CEOs for advice, insights, expertise and access to capital. It is also a campaigner for change across special interest areas including AI, Government engagement and DE&I. Software leaders, CEOs, NEDs and Chairs can access the programme and platform at no cost. The Boardwave community is generously supported and funded by a network of 85+ Partners from across the software investor and advisory ecosystem. www.boardwave.org

View source version on businesswire.com: https://www.businesswire.com/news/home/20240918041701/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom